Seer Operating Income 2021-2022 | SEER
Seer operating income from 2021 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
| Seer Annual Operating Income (Millions of US $) |
|
|---|---|
| 2021 | $ |
| 2020 | $ |
| Seer Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.445B | $0.007B |
| Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $164.215B | 9.99 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| QIAGEN (QGEN) | Netherlands | $10.343B | 16.33 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.057B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.540B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.675B | 7.17 |
| Arcus Biosciences (RCUS) | United States | $1.287B | 32.64 |
| Myovant Sciences (MYOV) | United Kingdom | $0.927B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.486B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.347B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.336B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.154B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.113B | 23.10 |
| SQZ Biotechnologies (SQZ) | United States | $0.094B | 0.00 |
